Whilst the repurposing of other SGLT2 inhibitors, dapa and empa, has been proposed in the setting of anti-cancer drug-induced cardiotoxicity [[16], [17], [18], [19]], it is cana's off-target effects that make it an attractive therapeutic prospect for T-ALL. Here, SLC5A2 is linked to cancer.